Evaluating Akums Drugs & Pharmaceuticals Ltd IPO opportunity; Should you invest?

Evaluating Akums Drugs & Pharmaceuticals Ltd IPO opportunity; Should you invest?

Mandar Wagh
/ Categories: Trending, IPO, IPO Analysis

In this analysis, we take a closer look at Akums Drugs & Pharmaceuticals Ltd and present you with the exclusive IPO details.

About the issue  

Akums Drugs & Pharmaceuticals Ltd is set to launch its initial public offering (IPO) for equity shares, each with a face value of Rs 2. The IPO price range is set between Rs 646 and Rs 679 per equity share, resulting in a total issue size of Rs 1,856.74 crore at the upper price band.  

The IPO is scheduled to commence on July 30, 2024 and conclude on August 01, 2024. The market lot size for the IPO is 22 shares, with the option to apply for multiples of this lot. Individual retail investors have the opportunity to apply for a maximum of 13 lots, equivalent to 286 shares or a total investment of Rs 1,94,194 assuming the upper price band.

IPO Details
IPO Opening Date  July 30, 2024
IPO Closing Date  August 01, 2024
Issue Type  Book Built Issue IPO
Face Value Rs 2 per equity share
IPO Price  Rs 646 to Rs 679 per equity share
Min Order Quantity  22 shares
Listing At  BSE, NSE
Total Issue 27,345,162 shares of FV Rs 2*
(Aggregating up to Rs 1,856.74 Cr)*
Fresh Issue 10,014,727 shares of FV Rs 2*
(Aggregating up to Rs 680.00 Cr)*
Offer for Sale 17,330,435 shares of FV Rs 2*
(Aggregating up to Rs 1,176.74 Cr)*
QIB Shares Offered  75% of the Offer
Retail Shares Offered  10% of the Offer
NII (HNI) Shares Offered 15% of the Offer
*At Upper Price Band  

Objects of the Issue  

The offer encompasses both the fresh issue and the offer for sale. It's important to note that the company will not accrue any proceeds from the offer for sale. The company plans to allocate the net proceeds raised from the fresh issue for the following purposes:

1. Repayment/ prepayment of indebtedness of the company and its subsidiaries

2. Funding incremental working capital requirements of the company

3. Pursuing inorganic growth initiatives through acquisitions

4. General corporate purposes

Promoter holding  

Sanjeev Jain, Sandeep Jain, and Akums Master Trust are the promoters of the company. The promoters and promoter group currently hold a pre-issue shareholding stake of 82.48 per cent in the company.

DSIJ's 'Value Pick' service recommends long-term stocks based on Value Investing Philosophy. If this interests you, do download the service details here.

Company profile  

Established in 2004, Akums Drugs & Pharmaceuticals Ltd is a leading pharmaceutical contract development and manufacturing organisation (CDMO). It offers a comprehensive range of pharmaceutical products and services both in India and internationally. The company’s core business is centred on providing end-to-end product development and manufacturing solutions to its clients.

In addition, the company is engaged in formulation research and development, preparation and filing of regulatory dossiers in both Indian and global markets, testing services, and the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). As a CDMO, the company produces an extensive range of dosage forms, including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others.

Since its inception, the company Ltd has manufactured more than 4,000 commercialized formulations across over 60 dosage forms. For its CDMO business, the company operates 10 manufacturing units with a cumulative formulation manufacturing capacity of 49.23 billion units annually as of March 31, 2024. Additionally, it expects its new injectable facility to become operational in FY25.

As of March 31, 2024, key clients for company’s CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr Reddy’s Laboratories, Mankind Pharma, MedPlus Health Services, Natco Pharma, and Sun Pharmaceutical Industries, among others.

Financials  

Rs (in crore) FY22 FY23 FY24
Revenue 3,695 3,701 4,212
Profit before tax (PBT) -193 150 -45
Net Profit -251 98 0.79

During the FY24, Akums Drugs & Pharmaceuticals Ltd held a market share of 30 per cent of the Indian domestic CDMO market by value, an increase from 26.7 per cent during the FY21. Despite the increase in revenue, concerns about profitability persist due to several significant costs, with 'Fair value changes to financial instruments' being a major factor. Understanding this element is crucial for a comprehensive financial analysis.

Rights Waiver and Financial Impact Explained

The Investor has waived its rights that required the Holding Company to buy back equity shares as per the shareholder's agreement, and the subsequent waiver cum amendment agreement. As a result, the Holding Company is no longer obligated to repurchase the investor's equity shares if it, or its Promoters, cannot facilitate an exit for the investor as initially stipulated.

The management clarified that the put-call liabilities for recent contract adjustments were necessary under GAAP measures due to the lack of additional funding. Excluding these accounting provisions, the company posted a net profit of Rs 243.30 crore in FY22, Rs 53.85 crore in FY23, and Rs 358.56 crore in FY24. This completely changes the financial picture of the company.

Rs (in crore) FY22 FY23 FY24
Net Profit (without put option impact) 243 54 359

Valuation and outlook  

Company Name P/E P/B RoE (%)
Akums Drugs & Pharmaceuticals Ltd 30 14 17
Listed Peers
Divi's Laboratories Ltd 78 9 12
Suven Pharmaceuticals Ltd 80 12 16
Gland Pharma Ltd 43 4 10
Torrent Pharmaceuticals Ltd 61 15 25
Alkem Laboratories Ltd 35 6 11
Eris Lifesciences Ltd 37 6 18
JB Chemicals & Pharmaceuticals Ltd 53 10 19
Mankind Pharma Ltd 44 9 23
Innova Captab Ltd 38 4 28

*Based on the restated financial data and excluding the impact of the put option, the issue is priced at a P/E ratio of 30, based on FY24 financial data. The issue is priced with a P/BV ratio of 13.69 times, calculated using its Net Asset Value (NAV) of Rs 49.59 as of March 31, 2024.

Taking into account both valuations and returns, the company has outperformed its listed peers. Hence, we recommend investors subscribe to the issue with a long-term perspective.

Previous Article Double Dhamaka! Board likely to announce stock split & interim dividend; Beverages company’s stock trades at high ROE & high ROCE
Next Article Heavy buying and 1,000 per cent returns: Back-to-back upper circuit in this multibagger stock; bags new order from ONGC!
Rate this article:
4.2

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR